Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion of its clinical partnership with Shanghai East Hospital, a Class 3A general hospital in China. This strategic collaboration aims to address the increasing demand for clinical studies within the country.
The two entities initially collaborated in 2019, focusing on clinical research in neurology, cardiology, and oncology. Building on this foundation, the renewed partnership will delve deeper into oncology, metabolism, Alzheimer’s disease, and other therapeutic areas, strengthening their joint commitment to advancing medical research and patient care.- Flcube.com
